Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
Telix today provides an update on its commercial and operational performance for the quarter ended 31 December 2024 (Q4...
Read moreLatest News
Category: ASX
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
Telix today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx (Zircaix®, 89Zr- girentuximab) kidney cancer...
Read more
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
Telix today announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nuclear medicine. Telix’s development program...
Read more
Telix ADSs Commence Trading on Nasdaq
Telix announces that its American Depository Shares (ADSs) have commenced trading on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol...
Read more
Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
Telix today announces that it has entered into a technology collaboration and licence agreement with Berlin-based Eckert & Ziegler SE (EZAG) for the use of EZAG’s cyclotron-based systems to produce...
Read more
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
Telix today welcomes the announcement by the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) that it will pay separately for specialised diagnostic radiopharmaceuticals for Medicare Fee for...
Read more
FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara®), an agent for the imaging of glioma....
Read more
Telix Files Form 20-F Registration Statement for Nasdaq ADS
Telix announces that it has publicly filed a Form 20-F registration statement (Registration Statement) with the United States (U.S.) Securities and Exchange Commission (SEC) relating to a proposed listing of...
Read more
Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M
Telix today provides an update on its revenue and operational performance for the quarter ended 30 September 2024 (Q3...
Read more
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
Telix and RLS (USA) Inc., America’s only Joint Commission-accredited radiopharmacy network distributing PET, SPECT and therapeutic radiopharmaceuticals, today announced an agreement by the Company to acquire RLS from its parent...
Read more